Abstract 145P
Background
Glasgow prognostic score (GPS), which is defined with serum levels of two parameters, albumin >3.5 g/dl and C-reactive protein <1.0 mg/dl (both as 0, either as 1, and neither as 2), has a prognostic significance in various malignant solid tumors. In a small-scale retrospective study, GPS was useful as a prognostic factor for chemo-naïve advanced biliary tract cancer (ABTC) patients with good performance status (PS; defined with ECOG PS 0 and 1). We evaluated whether GPS was useful in large-scale prospective study for ABTC patients with good PS.
Methods
ABTC patients with PS 0/1 and not missing laboratory data among the patients who received gemcitabine + cisplatin (GC) or GC + S-1 (GCS) in a phase III study (MITSUBA) were analyzed for factors with P < 0.2, using multivariate Cox proportional hazards model for overall survival (OS). In the exploratory analysis, OS was compared between GC and GCS according to GPS.
Results
Clinical data were collected from 230 patients (113 patients in the GC arm and 117 patients in the GCS arm) among 241 patients. The proportion of patients was 43% in GPS 0, 35% in GPS 1, and 22% in GPS 2, respectively. In the univariate and multivariate analyses, GPS was an independent prognostic factor (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.56-0.81; P < 0.001). The median OS was 18.0 months (95%CI, 15.3-20.7), 12.6 months (95%CI, 11.4-13.8), and 7.2 (95%CI, 4.4-10.0) for patients with GPS 0, GPS 1, and GPS 2, respectively. The HRs of GCS to GC were 1.00 (95%CI, 0.64-1.55; P = 0.99), 0.72 (95%CI, 0.45-1.15; P = 0.17), and 0.57 (95%CI, 0.32-1.04; P = 0.07), for patients with GPS 0, GPS 1, and GPS 2, respectively.
Conclusions
GPS was useful for chemo-naïve ABTC patients with good PS, and GCS might improve OS, especially in patients with poor prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kansai Hepato-Biliary Oncology Group.
Funding
Taiho Pharmaceutical.
Disclosure
T. Moriwaki: Speaker Bureau / Expert testimony: Taiho Pharmaceutical; Speaker Bureau / Expert testimony: Lilly. Y. Yamamoto: Speaker Bureau / Expert testimony: Taiho. T. Yamada: Advisory / Consultancy: Taiho; Speaker Bureau / Expert testimony: Lilly. A. Taketomi: Honoraria (institution), Leadership role: Taiho. K. Yoshimura: Honoraria (self): Taiho; Honoraria (self): Lilly; Honoraria (self): Nippon Kayaku. E. Hatano: Honoraria (self): Taiho; Honoraria (self), Advisory / Consultancy: Lilly. T. Ioka: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Taiho. All other authors have declared no conflicts of interest.
Resources from the same session
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract